Aetna modified CPB 0001 for transrectal ultrasound, effective March 7, 2026. Here's what billing teams need to know before submitting claims under CPT 76872 and 76873.
Aetna, a CVS Health company, updated its transrectal ultrasound coverage policy under CPB 0001 on March 7, 2026. The policy governs reimbursement for CPT codes 76872 and 76873—the two primary codes for transrectal ultrasound (TRUS) procedures. The change clarifies both covered indications and a growing list of experimental designations that will drive claim denials if your team isn't paying attention.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Transrectal Ultrasound — CPB 0001 |
| Policy Code | CPB 0001 |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | Medium |
| Specialties Affected | Urology, Colorectal Surgery, Radiation Oncology, Gastroenterology, Reproductive Medicine |
| Key Action | Audit charge capture for CPT 76872 and 76873 and verify diagnosis codes map to a covered indication before the March 7, 2026 effective date |
Aetna Transrectal Ultrasound Coverage Criteria and Medical Necessity Requirements 2026
The Aetna transrectal ultrasound coverage policy under CPB 0001 ties medical necessity directly to the clinical indication. Aetna does not consider TRUS broadly covered—your claim needs a diagnosis that matches one of the specific criteria below. If it doesn't, expect a denial.
Aetna covers CPT 76872 (transrectal ultrasound) and CPT 76873 (prostate volume study for brachytherapy treatment planning) when the member has at least one of the following conditions:
| # | Covered Indication |
|---|---|
| 1 | Prostate biopsy — covered under a separate policy, CPB 0698 (Prostate Saturation Biopsy). Don't bill 76872 for biopsy guidance without confirming the specific biopsy criteria in that bulletin. |
| 2 | Anal sphincter dysfunction — assessment of sphincter function qualifies. |
| 3 | Prostate cancer staging — clinical staging of a confirmed prostate cancer diagnosis (ICD-10 C61). |
| 4 | Rectal carcinoma staging — clinical staging of rectal cancer (ICD-10 C19–C21.8). |
| 5 | Brachytherapy planning — CPT 76873 is specifically tied to determining prostate volume before brachytherapy. This is one of the clearest covered use cases in the policy. |
| 6 | Anal and/or rectal fistula — evaluation of fistula (ICD-10 K60.30–K60.529). |
| 7 | Anal and/or rectal peri-rectal abscesses — evaluation of abscess (ICD-10 K61.0–K61.2). |
| 8 | Hematospermia (hemospermia) — to distinguish idiopathic from secondary causes. |
| 9 | Malignant or benign peri-rectal tumors — evaluation of tumor burden. |
| 10 | Recurrent rectal carcinoma — follow-up evaluation in members with prior definitive treatment for rectal carcinoma where recurrence is suspected. |
| 11 | Infertility and azoospermia — when ejaculatory duct cyst is suspected. Note: Aetna flags this one explicitly. Some benefit plans exclude infertility services entirely. Check the member's specific plan before billing. |
| 12 | Metastatic lesions of unknown primary with PSA > 10 ng/mL — when prostatic origin is a reasonable differential. |
Medical necessity for TRUS is indication-specific. A claim for CPT 76872 without a diagnosis that maps to one of these criteria will not pass Aetna's coverage policy. Your coders need to know which ICD-10 codes correspond to each indication before submitting.
The policy doesn't explicitly state prior authorization requirements for these procedures. That said, prior auth requirements can vary by plan and market. If you're billing for a high-cost scenario—like brachytherapy planning with 76873 alongside a full brachytherapy CPT suite—verify PA status with the specific plan before the procedure date.
Aetna Transrectal Ultrasound Exclusions and Non-Covered Indications
Aetna draws a hard line here. Nine specific procedures and approaches are classified as experimental, investigational, or unproven under CPB 0001. Filing claims for these will result in denial, and there's no pathway to medical necessity override for an experimental designation.
The experimental list includes technologies that may seem clinically promising but lack sufficient evidence to meet Aetna's coverage threshold:
| # | Excluded Procedure |
|---|---|
| 1 | Biplane TRUS combined with elastosonography plus contrast-enhanced ultrasound for rectal cancer staging — CPT 76872 with add-on imaging enhancements falls into non-covered territory when used for this specific combination. |
| 2 | High-resolution micro-ultrasound-guided prostate biopsy — CPT codes 76376, 76377, 76856, 76978, 76979 are explicitly listed as not covered for this indication. |
| 3 | Intraoperative MRI/ultrasound fusion optimization for low-dose-rate prostate brachytherapy — not covered under this policy. |
| 4 | Photoacoustic imaging for prostate cancer angiogenesis — no coverage. |
| 5 | PET image-directed, 3D ultrasound-guided prostate biopsy — CPT 78812 is listed as not covered for this use. |
| 6 | 3D transrectal and transabdominal ultrasound image fusion for gynecologic brachytherapy guidance — non-covered. |
| 7 | TRUS as a prostate disease screening test — routine prostate screening via TRUS is not a covered indication. This is distinct from clinical staging of a known cancer. |
| 8 | TRUS elastography (sono-elastography or shear-wave elastography) for prostate cancer evaluation — CPT codes 76981, 76982, and 76983 are not covered for this use. This one catches billing teams off guard when elastography is performed alongside a covered TRUS study. |
| 9 | TRUS for cervical cancer — despite the ICD-10 cervical cancer codes appearing in the related code list, TRUS as a primary evaluation tool for cervical cancer is experimental under this policy. |
The real exposure here is elastography. Many urology and radiology groups routinely add 76981 or 76982 when performing TRUS. Under this coverage policy, Aetna will not reimburse those codes for prostate cancer evaluation. If your group uses elastography as part of a standard TRUS workflow, you need to separate the billing or accept that Aetna won't pay for the elastography component.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Prostate biopsy | Covered (see CPB 0698) | 76872 | Must meet separate biopsy criteria in CPB 0698 |
| Anal sphincter dysfunction assessment | Covered | 76872 | — |
| Prostate cancer clinical staging | Covered | 76872, C61 | — |
| Rectal carcinoma clinical staging | Covered | 76872, C19–C21.8 | — |
| Prostate volume for brachytherapy planning | Covered | 76873 | Strongest standalone covered use case |
| Anal/rectal fistula evaluation | Covered | 76872, K60.30–K60.529 | — |
| Peri-rectal abscess evaluation | Covered | 76872, K61.0–K61.2 | — |
| Hematospermia evaluation | Covered | 76872 | — |
| Malignant or benign peri-rectal tumors | Covered | 76872 | — |
| Recurrent rectal carcinoma follow-up | Covered | 76872 | Member must have had prior definitive treatment |
| Infertility/azoospermia (ejaculatory duct cyst suspected) | Covered (plan-dependent) | 76872 | Verify infertility benefit before billing |
| Metastatic unknown primary, PSA > 10 ng/mL | Covered | 76872 | PSA threshold is a hard requirement — document it |
| TRUS screening for prostate disease | Not Covered | 76872 | Experimental/investigational |
| TRUS elastography for prostate cancer | Not Covered | 76981, 76982, 76983 | Experimental — high denial risk |
| High-resolution micro-US-guided prostate biopsy | Not Covered | 76376, 76377, 76856, 76978, 76979 | Experimental |
| PET image-directed 3D US-guided prostate biopsy | Not Covered | 78812 | Experimental |
| Biplane TRUS + elastosonography + contrast-US for rectal cancer staging | Not Covered | 76872 (with enhancements) | Experimental |
| 3D US image fusion for gynecologic brachytherapy | Not Covered | — | Experimental |
| Intraoperative MRI/US fusion for LDR brachytherapy | Not Covered | — | Experimental |
| Photoacoustic imaging for prostate angiogenesis | Not Covered | — | Experimental |
| TRUS for cervical cancer | Not Covered | — | Experimental |
Aetna Transrectal Ultrasound Billing Guidelines and Action Items 2026
The effective date of March 7, 2026 is your hard deadline. Claims for dates of service on or after that date fall under this revised coverage policy. Here's what to do now:
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for CPT 76872 and 76873. Pull the last 90 days of claims for these codes billed to Aetna. Confirm each claim links to a covered indication with a supporting ICD-10 code. Flag any claims where the diagnosis is screening-related (PSA screening, routine prostate exam) or where elastography codes were added. |
| 2 | Remove CPT 76981, 76982, and 76983 from TRUS order sets for Aetna patients. These elastography codes are explicitly non-covered for prostate cancer evaluation. If your group routinely adds them to TRUS studies, update your charge capture templates before March 7, 2026. This is the highest-risk line item in this policy for urology and radiology billing teams. |
| 3 | Verify the PSA threshold for metastatic unknown primary cases. For claims tied to metastatic lesions of unknown primary, the medical record must document a PSA level greater than 10 ng/mL. Without it, the claim doesn't meet medical necessity criteria. Make sure your documentation workflow captures this value before the claim goes out. |
| 4 | Check infertility benefit status before billing TRUS for azoospermia. Aetna covers this indication—but only if the member's plan includes infertility benefits. This isn't a blanket coverage policy. Pull the member's EOB or call Aetna eligibility before the procedure date. A denied infertility claim is harder to appeal after the fact. |
| 5 | Separate prostate biopsy claims into CPB 0698. Aetna directs prostate biopsy coverage to a separate clinical policy bulletin—CPB 0698. If you're billing 76872 for biopsy guidance, the medical necessity criteria from CPB 0001 alone aren't enough. Confirm the biopsy meets CPB 0698 criteria independently. |
| 6 | Update denial management workflows for experimental codes. If your team receives a denial on 76978, 76979, 76376, or 78812 for prostate-related procedures, don't assume appeal will work. These codes are experimental under CPB 0001. An appeal on experimental grounds requires clinical trial documentation or a medical exception process—not just a letter of medical necessity. Brief your appeals team before March 7, 2026. |
If you bill across multiple specialties—urology, colorectal surgery, radiation oncology, and GI—talk to your compliance officer before the effective date. The experimental designations in this policy create real claim denial exposure across different service lines, and the risk isn't uniform. A colorectal surgeon's use of 76872 for rectal staging is covered. The same code billed for a gynecologic brachytherapy guidance application is not.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Transrectal Ultrasound Under CPB 0001
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 45341 | CPT | Sigmoidoscopy, flexible: with endoscopic ultrasound examination |
| 76872 | CPT | Ultrasound, transrectal (TRUS combined with USG elastosonography plus contrast-enhanced USG not covered) |
| 76873 | CPT | Prostate volume study for brachytherapy treatment planning (separate procedure) |
Not Covered / Experimental CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 76376 | CPT | 3D rendering with interpretation and reporting of CT, MRI, ultrasound | High-resolution micro-ultrasound-guided prostate biopsy — not covered |
| 76377 | CPT | 3D rendering with interpretation and reporting of CT, MRI, ultrasound | High-resolution micro-ultrasound-guided prostate biopsy — not covered |
| 76856 | CPT | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | High-resolution micro-ultrasound-guided prostate biopsy — not covered |
| 76978 | CPT | Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac) | High-resolution micro-ultrasound-guided prostate biopsy — not covered |
| 76979 | CPT | Each additional lesion with separate injection (add-on) | High-resolution micro-ultrasound-guided prostate biopsy — not covered |
| 76981 | CPT | Ultrasound, elastography | Experimental — not covered for TRUS elastography (prostate cancer evaluation) |
| 76982 | CPT | Ultrasound, elastography | Experimental — not covered for TRUS elastography (prostate cancer evaluation) |
| 76983 | CPT | Ultrasound, elastography | Experimental — not covered for TRUS elastography (prostate cancer evaluation) |
| 78812 | CPT | Positron emission tomography (PET) imaging; skull base to mid-thigh | PET image-directed 3D US-guided prostate biopsy — not covered |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C19–C21.8 | Malignant neoplasm of rectosigmoid junction, rectum, anus and anal canal |
| C53.0–C53.9 | Malignant neoplasm of cervix uteri |
| C61 | Malignant neoplasm of prostate |
| C76.3 | Malignant neoplasm of pelvis |
| C78.5 | Secondary malignant neoplasm of large intestine and rectum |
| C79.82 | Secondary malignant neoplasm of genital organs |
| D01.1–D01.3 | Carcinoma in situ of rectosigmoid junction, rectum, anus and anal canal |
| D06.0–D06.9 | Carcinoma in situ of cervix uteri |
| D07.5 | Carcinoma in situ of prostate |
| D12.7–D12.9 | Benign neoplasm of rectosigmoid junction, rectum, anus and anal canal |
| D29.1 | Benign neoplasm of prostate |
| D37.5 | Neoplasm of uncertain behavior of rectum |
| D40.0 | Neoplasm of uncertain behavior of prostate |
| K60.30–K60.529 | Fistula of anal and rectal regions |
| K61.0–K61.2 | Abscess of anal and rectal regions |
Get the Full Picture for CPT 76872
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.